Table Graph
      published meta-analysis   sensitivity analysis   studies

stem cells in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsLanzoni, 2021 0.14 [0.02; 0.96] Shi, 2020 0.53 [0.01; 27.55] 0.18[0.03; 1.02]Lanzoni, 2021, Shi, 202020%124moderatenot evaluable deathsdetailed resultsLanzoni, 2021 0.11 [0.01; 0.93] Shi, 2020 0.53 [0.01; 27.55] 0.16[0.03; 1.02]Lanzoni, 2021, Shi, 202020%124moderatenot evaluable deaths (time to event analysis only)detailed resultsLanzoni, 2021 0.11 [0.01; 0.93] 0.11[0.01; 0.93]Lanzoni, 202110%24NAnot evaluable recoverydetailed resultsLanzoni, 2021 3.46 [1.05; 11.35] 3.46[1.05; 11.35]Lanzoni, 202110%24NAnot evaluable serious adverse eventsdetailed resultsLanzoni, 2021 0.10 [0.01; 0.69] Shi, 2020 1.08 [0.04; 32.96] 0.21[0.02; 1.86]Lanzoni, 2021, Shi, 2020229%124moderatenot evaluable adverse eventsdetailed resultsLanzoni, 2021 0.18 [0.02; 1.95] Shi, 2020 0.88 [0.38; 2.03] 0.60[0.16; 2.26]Lanzoni, 2021, Shi, 2020234%124moderatenot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-04-27 16:32 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 534 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons